BCAX
Bicara Therapeutics Inc. Common Stock · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow -7.6% ·
net new positions +11.1%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 70 | +5 | 22.18M | $657.51M | +10 | −5 |
| Q1 2026 | 68 | +4 | 22.46M | $446.36M | +8 | −5 |
| Q4 2025 | 65 | 0 | 22.60M | $380.21M | +3 | −2 |
| Q3 2025 | 13 | -1 | 12.02M | $189.85M | — | −2 |
| Q2 2025 | 12 | 0 | 11.43M | $106.16M | +3 | −3 |
| Q1 2025 | 9 | +1 | 5.34M | $69.55M | +2 | −1 |
| Q4 2024 | 8 | -3 | 5.77M | $100.60M | +1 | −4 |
| Q3 2024 | 10 | +10 | 4.16M | $105.86M | +10 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 1.80M | +16.2% | $23.43M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 1.80M | +16.2% | $23.43M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.39M | +84.0% | $18.17M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.39M | +84.0% | $18.17M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.39M | +84.0% | $18.17M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.39M | +84.0% | $18.17M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Adage Capital Partners ✦ | 1.18M | -45.6% | $15.41M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 491.65K | +5.4% | $6.41M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 491.65K | +5.4% | $6.41M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | State Street Global Advisors ✦ (passive) | 370.13K | +21.5% | $4.82M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 42.89K | -38.7% | $558,844 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | Millennium Management ✦ | 25.65K | -93.3% | $334,193 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 19.03K | New | $248,013 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 19.03K | New | $248,013 | 0.0% | New | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 19.03K | New | $248,013 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 19.03K | New | $248,013 | 0.0% | New | 1 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 12.77K | New | $166,393 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $248,013 | 0.0% |
| AQR Capital Management | $248,013 | 0.0% |
| AQR Capital Management | $248,013 | 0.0% |
| AQR Capital Management | $248,013 | 0.0% |
| Two Sigma Investments | $166,393 | 0.0% |
Exited
| Marshall Wace | $1.18M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 71.07M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 18.75K sh · $524,533
Officer, Director · 10.00K sh · $279,750
Officer · 12.50K sh · $349,591
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology